Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4485932 | 0.89 | HRH3 (1.00) | HRH3KCNH2 | |
| SCHEMBL4470194 | 0.87 | HRH3 (0.96) | HRH3KCNH2 | |
| SCHEMBL4472017 | 0.86 | HRH3 (0.81) | HRH3KCNH2 | |
| SCHEMBL502075 | 0.82 | HRH3 (0.81) | HRH3KCNH2 | |
| SCHEMBL4476355 | 0.82 | HRH3 (0.81) | HRH3KCNH2 | |
| SCHEMBL4465628 | 0.81 | HRH3 (0.61) | HRH3KCNH2 | |
| SCHEMBL2004888 | 0.81 | HRH3 (0.75) | HRH3KCNH2 | |
| SCHEMBL4474301 | 0.80 | HRH3 (0.63) | HRH3KCNH2 | |
| SCHEMBL4478962 | 0.80 | HRH3 (0.64) | HRH3KCNH2 | |
| SCHEMBL4470902 | 0.79 | HRH3 (0.81) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | claimed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | claimed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | claimed |
| EP-3243385-B1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| US-9932311-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9868733-B2 | Azabenzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9593155-B2 | Oxyntomodulin analogs | MERCK SHARP & DOHME CORP. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9556193-B2 | Benzimidazole hexahydrofuro[3,2-b]furan derivatives | Merck Shapr & Dohme Corp. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9540364-B2 | Benzimidazole tetrahydrofuran derivatives | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9527839-B2 | Benzimidazole tetrahydropyran derivatives | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2010519-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| WO-2008091631-A1 | SUBSTITUTED AMINOPYRIMIDINES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-1940842-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007120655-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244048-A1 | Neuromedin U receptor agonists and uses thereof | MERCK SHARP & DOHME CORP. | 2007-10-18 | — | — | US | disclosed |
| WO-2007041052-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | HRH3 3/4885KCNH2 299/4885 |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | HRH3 48/4885KCNH2 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.